Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 19739 | 427 | 27.2 | 41% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | BOVINE BETALACTOGLOBULIN | Author keyword | 1 | 100% | 0% | 2 |
| 2 | MUCOSAL ANTIGENS | Author keyword | 1 | 100% | 0% | 2 |
| 3 | BR AMBEDKAR ROTARY CANC HOSP | Address | 1 | 50% | 0% | 1 |
| 4 | LONG LASTING CHANGES | Author keyword | 1 | 50% | 0% | 1 |
| 5 | OVARIAN CANCER PROGNOSIS | Author keyword | 1 | 50% | 0% | 1 |
| 6 | PHYTOHEMAGGLUTININ RESPONSE | Author keyword | 1 | 50% | 0% | 1 |
| 7 | RADIATION INDUCED APLASIA | Author keyword | 1 | 50% | 0% | 1 |
| 8 | TH PROFILE | Author keyword | 1 | 50% | 0% | 1 |
| 9 | TREATMENT RELATED TOXICITIES | Author keyword | 1 | 50% | 0% | 1 |
| 10 | AZIENDA OSPED G SALESI | Address | 0 | 33% | 0% | 1 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | MALIGNANT CERVICAL NEOPLASIA | 3 | 57% | 1% | 4 |
| 2 | LEVAMISOLE IMMUNOTHERAPY | 1 | 100% | 0% | 2 |
| 3 | BLOOD LYMPHOCYTE POPULATION | 1 | 50% | 0% | 1 |
| 4 | INDUCED LYMPHOCYTOPENIA | 1 | 50% | 0% | 1 |
| 5 | LYMPHOCYTE IMMUNITY | 1 | 50% | 0% | 1 |
| 6 | MALIGNANT BREAST DISEASE | 1 | 50% | 0% | 1 |
| 7 | PERIPHERAL LYMPHOCYTE | 1 | 50% | 0% | 1 |
| 8 | LOCAL RADIATION THERAPY | 1 | 17% | 1% | 3 |
| 9 | IMMUNOLOGICAL RESPONSIVENESS | 1 | 22% | 0% | 2 |
| 10 | TUMOR DISEASE | 0 | 33% | 0% | 1 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Adjuvant breast cancer vaccine improves disease specific survival of breast cancer patients with depressed lymphocyte immunity | 2013 | 5 | 18 | 33% |
| IMMUNOLOGICAL PHENOMENA IN HUMAN ORAL-CARCINOMA IN INDIA | 1993 | 2 | 25 | 68% |
| IMMUNOLOGICAL ABNORMALITIES IN ORAL PRECANCERS | 1991 | 1 | 24 | 58% |
| ONCOGENESIS OF SQUAMOUS CARCINOMA OF THE UTERINE CERVIX | 1992 | 9 | 62 | 15% |
| PRESENT STATUS OF TUMOR IMMUNOLOGY IN CLINICAL GYNECOLOGY | 1989 | 5 | 5 | 20% |
| IMMUNOLOGY AND ORAL-CANCER | 1983 | 5 | 5 | 60% |
| NATURAL-KILLER-CELLS DYNAMICS IN SOLID TUMOR TREATMENT | 1990 | 0 | 23 | 30% |
| IMMUNOMODULATING EFFECTS OF A SHORT-TERM ORAL TREATMENT WITH C-1821 IN UNTREATED CANCER-PATIENTS - A CONTROLLED-STUDY | 1983 | 0 | 3 | 100% |
| IMMUNOLOGY OF SQUAMOUS-CELL CARCINOMA OF THE AERODIGESTIVE TRACT AND THE PROSPECTS FOR IMMUNOTHERAPY | 1995 | 3 | 128 | 11% |
| HISTORICAL ASPECTS OF TYLECTOMY AND RADIATION-THERAPY IN THE TREATMENT OF CANCER OF THE BREAST | 1982 | 0 | 1 | 100% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | BR AMBEDKAR ROTARY CANC HOSP | 1 | 50% | 0.2% | 1 |
| 2 | AZIENDA OSPED G SALESI | 0 | 33% | 0.2% | 1 |
| 3 | CENT HOSP ANAESTHESIOL | 0 | 33% | 0.2% | 1 |
| 4 | STANDARD DOSIMETRY | 0 | 33% | 0.2% | 1 |
| 5 | ROBERT BO HOSP | 0 | 25% | 0.2% | 1 |
| 6 | MED LORY HAUS | 0 | 20% | 0.2% | 1 |
| 7 | SECT RADIAT THER Y | 0 | 20% | 0.2% | 1 |
| 8 | CHILD CARE PEDIAT | 0 | 13% | 0.2% | 1 |
| 9 | SECT CENT NERVOUS SYST PHARMACOL | 0 | 13% | 0.2% | 1 |
| 10 | CENT HOSP SURG | 0 | 10% | 0.2% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000274063 | WHOLE BLOOD CELL CULTURES//COLORIMETRY METHOD//HUMAN COLORECTAL TUMORS |
| 2 | 0.0000218652 | IMMUNE SUPPRESSOR CELLS//IRX 2//SERV 151Z2 |
| 3 | 0.0000136621 | POSTOPERATIVE SEPTIC COMPLICATIONS//BRIAN MIND//LOOSENING OF ENDOPROSTHESES |
| 4 | 0.0000113654 | IST MICROBIOL MED//IST PATOL MED 3//POSTSURGICAL CYTOKINE RELEASE |
| 5 | 0.0000103679 | RECOMBINANT VACCINE GRP//ABSCOPAL EFFECT//IMMUNOGENIC TUMOR CELL DEATH |
| 6 | 0.0000089598 | MED CHILDRENS HOSP FDN//PEDIAT SURG 219 BRYANT ST//PESQUISA SOBRE TIMO |
| 7 | 0.0000081651 | CD3 ZETA//ORAL BIOL ORAL MED//ZETA CHAIN |
| 8 | 0.0000073409 | TRANSPLACENTAL MUTAGENICITY//ANTITUMOR PREPARATIONS//CANA3DTPA |
| 9 | 0.0000070648 | LEVAMISOLE//AMINOREX//4 METHYLAMINOREX |
| 10 | 0.0000069801 | OK 432//OK432//PROD LIFECYCLE MED INFORMAT |